HomeAI · summaries
Storia in 3 fonti
Fierce Pharma Asia—Takeda’s historic narcolepsy nod; Daiichi’s accounting error; Astellas’ revenue beat
Takeda's first-in-class orexin treatment won an FDA nod in narcolepsy. Daiichi Sankyo faced investor pushback after admitting to an accounting error. | Takeda's first-in-class orexin treatment won an FDA nod for narcolepsy. Daiichi Sankyo faced investor pushback after admitting to an accounting error. Astellas booked a new quarterly revenue record. And more.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments
The FDA approved a novel type of treatment for narcolepsy made by Takeda, backing a new drug class that scientists hope can be used to treat other conditions.
- ·
endpoints.news
Let the orexin market begin: Takeda snags FDA approval for narcolepsy type 1 drug
Takeda's Orzeyful wins FDA approval as the first full-symptom narcolepsy type 1 drug, kicking off an orexin agonist race with Lilly and Alkermes close behind.
